Description
Nervisign (Pregabalin) 300 mg
Nervisign 300 mg is a pregabalin capsule. Pregabalin is a prescription medicine used for certain types of nerve pain and as add-on treatment for some seizure disorders. The exact trade name should be verified locally, but the active ingredient pregabalin is well established in regulatory prescribing information.
Active Ingredient and Medicine Class
The active ingredient is pregabalin, a gabapentinoid and anticonvulsant. Regulatory sources describe it as a gamma-aminobutyric acid (GABA) analogue, although it does not act directly on GABA receptors.
Established Medical Uses
Pregabalin is authorised for several established uses, including peripheral neuropathic pain, central neuropathic pain, and adjunctive treatment of partial seizures in epilepsy. In some jurisdictions it is also approved for other specific indications, such as anxiety disorders, but those uses vary by country and product label.
How It Works
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This reduces the release of certain excitatory neurotransmitters and helps dampen abnormal nerve signalling involved in neuropathic pain and seizures.
Important Safety Information
Important risks described in official labels include hypersensitivity reactions, angioedema, and respiratory depression, especially when pregabalin is used with other central nervous system depressants or in people with underlying respiratory impairment. Dose adjustment is required in renal impairment because the medicine is eliminated mainly by the kidneys. Labels also warn about peripheral edema and the potential for increased suicidal thoughts or behaviour seen with antiepileptic drugs.
Clinically significant interactions include additive sedation and respiratory depression with opioids, benzodiazepines, and other CNS depressants. Regulatory information also notes additive edema and weight gain with thiazolidinedione antidiabetic agents.
Possible Side Effects
Common adverse effects include dizziness, somnolence, dry mouth, blurred vision, peripheral edema, weight gain, fatigue, and difficulty with concentration or attention. More serious reactions can include severe allergic reactions, angioedema, breathing problems, and mood or behaviour changes.
Scientific Evidence
Peer-reviewed reviews and meta-analyses support pregabalin’s benefit in several neuropathic pain conditions and describe a predictable adverse-effect profile dominated by central nervous system effects such as dizziness and sleepiness. The overall evidence base also supports its role as adjunctive therapy in epilepsy, consistent with regulatory approvals.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, product label, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA), Pregabalin Viatris: EPAR / medicine overview
- U.S. Food and Drug Administration (FDA) / DailyMed, Pregabalin Capsules, prescribing information
- Toth C et al., Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain, Journal of Pain Research, 2014
